NCT00881257终止2 期
Multicenter Assessment of the Safety and Efficacy of the Minnow Medical GRST™ Peripheral Catheter System
适应症
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 78
- 试验地点
- 4
- 主要终点
- Major Adverse Clinical Events Rate
研究概览
简要总结
The objective of this clinical investigation is to evaluate the safety and efficacy of the Minnow Medical GRST™ Peripheral Catheter System in the treatment of de novo lesions in the superficial femoral artery (SFA) or the popliteal artery.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient is ≥18 of age.
- •Patient is Rutherford category 2-
- •De novo single lesion with a diameter stenosis (%DS) of ≥50%
- •Target lesion is a de novo occlusion that can be successfully pre-dilated resulting in a lesion of <99%.
- •Target lesion stenosis has a length of ≤100 mm based on visual assessment.
- •Target vessel reference diameter is ≥3.0 mm and ≤7.0 mm based on visual assessment.
- •Angiographic evidence of distal runoff defined as minimum one patent tibial artery with a straight flow to the foot.
- •Patient is willing and able to provide written informed consent prior to any study specific procedure.
- •Patient is willing and able to comply with specified follow-up evaluations at the specified times.
排除标准
- •Prior PTA in the intended target lesion including 10 mm proximal or distal from the intended treatment area.
- •Evidence of thrombus in the target vessel.
- •Prior ipsilateral or contralateral lower limb arterial bypass.
- •Treatment of ipsilateral lesions during the index procedure or planned treatment after the index procedure.
- •Target lesion is severely calcified.
- •Any known allergies and / or intolerances to the following: ASA, Clopidogrel, Heparin, contrast agents (that cannot be adequately pre-medicated).
- •Any planned surgery within 30 days of the study procedure.
- •Renal failure (serum creatinine > 2.0 mg/dL).
- •Female with childbearing potential without a negative pregnancy test.
- •Patient has had an organ transplant.
- •Patient is currently participating in an investigational drug or device study which has not reached the primary endpoint yet or which clinically interferes with the endpoints of this study.
- •In the investigator's opinion, the patient has a severe co-morbid condition(s) that could limit the ability to participate in the study.
结局指标
主要结局
Major Adverse Clinical Events Rate
时间窗: Up to 30 days
次要结局
- Binary Restenosis(30 days, 3 months, 6 months and 12 months)
- Target Lesion Revascularization(30 days, 3 months, 6 months and 12 months)
- Amputation Rate(30 days, 3 months, 6 months, and 12 months)
- Technical Success(Treatment)
- Serious Adverse Events rate, including Major Adverse Clinical Events(30 days, 3 months, 6 months, and 12 months)
研究者
研究点 (4)
Loading locations...
相似试验
Approved For Marketing
不适用
Study of the Human Anti-TNF Monoclonal Antibody in Patients With Active Rheumatoid ArthritisRheumatoid ArthritisNCT00649545Abbott
已完成
不适用
Clinical Investigation on the Use of Ophthalmic Solution Based on Sodium Hyaluronate in Treatment of Eye DiscomfortOcular DrynessNCT05777798SIFI SpA28
已完成
3 期
Safety and Effectiveness Evaluation of the Multi-Electrode Radiofrequency Balloon Catheter for the Treatment of Symptomatic Paroxysmal Atrial FibrillationAtrial FibrillationNCT03683030Biosense Webster, Inc.397
招募中
2 期
Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp SystemCardiomyopathiesCardiogenic ShockHeart FailureCongenital Heart DiseaseNCT06080074Stanford University50
进行中（未招募）
1 期
A multicentre study to assess the safety and efficacy of sodium hyaluronate (Hyalgan-F) produced by fermentation in knee psteoarthritis.Knee oasteoarthritisEUCTR2005-002735-27-LVFidia Farmaceutici SpA120